<DOC>
	<DOCNO>NCT02868567</DOCNO>
	<brief_summary>This study comprise 18-week open label safety tolerability trial . In study , total 35 subject primary lateral sclerosis PLS upper motor neuron predominate ALS enrol . At initial screen evaluation , baseline T25FW obtain . This baseline test repeat week 2 , 4 , 6 , 10 , 14 18 . The validity measure show MS study compare MSWS-12 ( 12 item walk scale ) CGI ( clinical global impression ) scale ( 35-37 ) . A consistent responder define improvement 3 4 Timed 25Foot Wwalk medication , compare baseline result medication .</brief_summary>
	<brief_title>Use Dalfampridin Primary Lateral Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>1 . Male female , aged 1870 ; 2 . Diagnosis upper motor neuron disease , compatible PLS may include upper motor neuron ( UMN ) predominant ALS , define upper motor neuron ( UMN ) feature least 2 body region examination . 3 . EMG within 3 month enrollment minimal evidence lower motor neuron disease , 4 . Time symptom onset &gt; 18 month 5 . No previous allergy dalfampradine 6 . No current exposure therapeutic agent target PLS ALS within 30 day enrollment . 7 . Must force vital capacity ( FVC ) ≥ 60 % expect 8 . Written inform consent prior screen present . 9 . Subjects stable dose take Riluzole least thirty day 10 . Impaired walking measure Hauser Index great 1 less 7 ( 2 6 , inclusive ) ; 11 . Mini Mental Status Score &gt; 22 deem PI capable providing inform consent follow trial procedure . 12 . Geographically accessible site . 13 . Women must able become pregnant ( e.g. , postmenopausal , surgically sterile , use adequate birth control method ) duration study three month study completion . Adequate contraception include : abstinence , hormonal contraception ( oral contraception , implanted contraception , inject contraception hormonal contraception , example patch contraceptive ring ) , intrauterine device ( IUD ) place ≥ 3 month , barrier method conjunction spermicide , another adequate method . 14 . Elicitable Motor evoke potential ( MEP ) record 75 % stimulator output , use monophasic , reverse direction , normal current mode pulse . 1 . History clinically significant liver disease , renal disease , peripheral neuropathy , serious peripheral vascular disease , know HSP + C9orf72 SPG4 mutation , medical condition felt exclusionary investigator ; 2 . Unwillingness sign inform consent reason investigator feel subject complete study ; 3 . Women pregnant , breastfeeding , try become pregnant ; 4 . Active cancer within previous 2 year , except treat basal cell carcinoma skin ; 5 . Subjects take experimental drug within 30 day prior enrollment ; 6 . Patient history seizure ; brain surgery , brain implant , metallic implant neck , cardiac pacemaker , cochlear implant , pierce body modification neck , know history TMS related complication sideeffects , tinnitus . 7 . Patient moderate severe renal impairment define calculated creatinine clearance ≤50 mL/minute ; 8 . Patient administer botulinum toxin low extremity within 6 month prior screen visit and/or expect receive botulinum toxin low extremity course study ; 9 . Patient know allergy pyridinecontaining substance inactive ingredient dalfampridine tablet ( colloidal silicon dioxide , hydroxypropyl methylcellulose , magnesium stearate , microcrystalline cellulose , polyethylene glycol , titanium dioxide ) ; 10 . Patient history drug alcohol abuse within past year ; 11 . Patient clinically significant abnormal laboratory value . 12 . Anything else , opinion SI , would place subject increase risk preclude subject 's full compliance completion study . 13 . Inability record MEP 75 % stimulator output use monophasic , reverse direction , normal current mode pulse due either inexcitable motor cortex , coexist condition prevent TMS perform study subject , inability tolerate procedure , cause .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>